AVRA Medical Robotics, Inc. Appoints Dr. Onur Toker to Accelerate Development of its Surgical Robotic System
AVRA Medical Robotics, Inc. (OTC Pink: AVMR) announced the appointment of Dr. Onur Toker as Senior Design Engineer, aimed at accelerating the development of their advanced surgical robotic system. Dr. Toker, previously of Florida Poly, specializes in tele-robotics and embedded systems. CEO Barry Cohen emphasized that Dr. Toker's expertise will enhance the company's surgical intelligence software, targeting precision in aesthetic procedures. The company is also working with an independent accounting firm to update its SEC periodic reports.
- Dr. Onur Toker's appointment is expected to accelerate the development of AVRA's surgical robotic system.
- His expertise in tele-robotics and sensors will enhance the company's surgical software capabilities.
- The company aims to prototype their next-generation aesthetics robot for a conference in September 2021.
- The press release lacks specific financial metrics that directly demonstrate growth or financial health.
Orlando, Florida, June 28, 2021 (GLOBE NEWSWIRE) -- AVRA Medical Robotics, Inc. (“AVRA” or “the Company”) (OTC Pink: AVMR) today announces the appointment of Dr. Onur Toker, a leading expert in electrical and computer engineering, as Senior Design Engineer to accelerate the development of its advanced surgical robotic system.
Dr. Toker joins AVRA from Florida Poly, where he is an associate professor in electrical and computer engineering focusing on hardware acceleration, field-programmable gate arrays (FPGA), embedded systems, tele-robotics, and sensors.
Explaining the significance of the appointment, Barry Cohen, AVRA Chairman & CEO, said: “Dr Toker’s leading-edge published work on Delay Sensitive Tele-robotics, the design of fiber optic sensors and image processing pressure sensors will give us a tremendous boost in the development of our surgical robotic system. With Dr Toker’s help, we should be able to speed up the delivery of the most sophisticated combination of imaging, guidance, targeting and intelligence to assist surgeons performing aesthetics and other skin resurfacing procedures.”
Dr. Toker added: “AVRA’s surgical intelligence software is being developed to enable surgeons to deliver a level of accuracy, precision and reproducibility never before seen, by enhancing a surgeon’s fine motor skills with the ability of a surgical robot to perform delicate tasks with absolute precision and my work in these areas should allow us to produce an even more sophisticated model far quicker than the original plans allowed”.
As Barry Cohen summed up: “Dr Toker will be using his knowledge and skill to help us deliver a prototype of our next-generation aesthetics robot surgeon in time for the prestigious 13th 5CC World Congress in Barcelona this September 2021.”
The Company continues to work with its new independent public accounting firm to become current in its SEC periodic reports in the near future.
For further information about AVRA Medical Robotics, visit http://www.avramedicalrobotics.com or contact the company at info@avramedical.com
About AVRA Medical Robotics
AVRA Medical Robotics, Inc., (OTC Pink: AVMR) is a medical software and artificial intelligence company building a medical robotic system combining artificial intelligence, machine learning and proprietary software.
AVRA, known for its advances in robotics and guidance systems, is developing a surgical robotic system that “robotizes” a wide range of surgical procedures using surgical, non-surgical devices, and instruments which are currently being performed by human hands.
AVRA’s initial focus in the medical robotic field is on the development of a treatment- independent precision guidance system, applicable to a variety of minimally and non-invasive procedures, to leverage the growing demand for practical medical robotic devices, with an initial focus on skin resurfacing aesthetic procedures.
AVRA more recently leveraged the sterilization elements of its research and development work on its medical robotic system to address current and future issues highlighted by the COVID-19 pandemic.
Forward Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or AVRA’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
For more information visit the Company’s website at www.avramedical.com. For further information contact the company at: info@avramedical.com
FAQ
Who is Dr. Onur Toker and what is his role at AVRA Medical Robotics?
What are Dr. Toker's previous experiences before joining AVRA?
How will Dr. Toker's appointment impact AVRA's capabilities?
What is the significance of the 13th 5CC World Congress for AVRA?
Is AVRA Medical Robotics current with its SEC reports?
